Enliven Therapeutics Q3 2025 net loss $20.1M; completed Phase 1b enrollment for ELVN-001 in CML

Enliven Therapeutics, Inc.

2025-Q3 EPS reported -$1.35

Completed enrollment of randomized Phase 1b cohorts of ENABLE trial of ELVN-001 in CML; on track for Phase 3 pivotal trial in 2026.
Cash, equivalents and marketable securities of $477.6M at Sep 30, 2025, expected to fund operations into first half 2029.
Net loss of $20.1M for Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M, G&A $6.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.